| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Stambouli, A El Bouri, M A Bellimam, T Bouayoun, N El Karn. Cultivation of Cannabis sativa L. in northern Morocco. Bulletin on narcotics. vol 57. issue 1-2. 2011-03-14. PMID:21338017. |
qualitative analysis using high performance liquid chromatography with diode array detection revealed the presence of both the acid and the decarboxylated form of the main cannabinoids, cannabidiol, thc and cannabinol, and gas chromatography/mass spectrometry was used for the characterization of minor cannibinoids. |
2011-03-14 |
2023-08-12 |
Not clear |
| Nicholas T Van Dam, Mitch Earleywin. Pulmonary function in cannabis users: Support for a clinical trial of the vaporizer. The International journal on drug policy. vol 21. issue 6. 2011-03-07. PMID:20451365. |
the cannabis vaporizer, a machine that heats the plant to release cannabinoids in a mist without smoke and other respiratory irritants, appears to have the potential to minimize respiratory complaints. |
2011-03-07 |
2023-08-12 |
Not clear |
| Fabrício A Moreira, Carsten T Wotja. Cannabinoids and anxiety. Current topics in behavioral neurosciences. vol 2. 2011-03-07. PMID:21309120. |
the term cannabinoids encompasses compounds produced by the plant cannabis sativa, such as delta9-tetrahydrocannabinol, and synthetic counterparts. |
2011-03-07 |
2023-08-12 |
Not clear |
| Celia J A Morgan, Gráinne Schafer, Tom P Freeman, H Valerie Curra. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. The British journal of psychiatry : the journal of mental science. vol 197. issue 4. 2011-03-02. PMID:20884951. |
street cannabis is known to contain varying levels of each cannabinoid. |
2011-03-02 |
2023-08-12 |
Not clear |
| Joseph Tam, Jie Liu, Bani Mukhopadhyay, Resat Cinar, Grzegorz Godlewski, George Kuno. Endocannabinoids in liver disease. Hepatology (Baltimore, Md.). vol 53. issue 1. 2011-03-02. PMID:21254182. |
endocannabinoids are lipid mediators of the same cannabinoid (cb) receptors that mediate the effects of marijuana. |
2011-03-02 |
2023-08-12 |
mouse |
| Tiziana Bisogno, Vincenzo Di Marz. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS & neurological disorders drug targets. vol 9. issue 5. 2011-03-01. PMID:20632970. |
the g-protein coupled receptors for Δ⁹-tetrahydrocannabinol, the major psychoactive principle of marijuana, are known as cannabinoid receptors of type 1 (cb₁) and 2 (cb₂) and play important functions in degenerative and inflammatory disorders of the central nervous system. |
2011-03-01 |
2023-08-12 |
Not clear |
| Wai M Liu, Daniel W Fowler, Angus G Dalgleis. Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. Current clinical pharmacology. vol 5. issue 4. 2011-03-01. PMID:20925645. |
cannabinoids, the active components of the cannabis plant, have some clinical merit both as an anti-emetic and appetite stimulant in cachexic patients. |
2011-03-01 |
2023-08-12 |
Not clear |
| Robert A Battisti, Steven Roodenrys, Stuart J Johnstone, Nicole Pesa, Daniel F Hermens, Nadia Solowi. Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution. Psychopharmacology. vol 212. issue 4. 2011-02-25. PMID:20721538. |
chronic cannabis use has been related to deficits in cognition (particularly memory) and the normal functioning of brain structures sensitive to cannabinoids. |
2011-02-25 |
2023-08-12 |
Not clear |
| G Hu, G Ren, Y Sh. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene. vol 30. issue 2. 2011-02-10. PMID:21057532. |
cannabinoids, the active ingredients in marijuana, have dramatic effects on various organ systems. |
2011-02-10 |
2023-08-12 |
Not clear |
| Kalpana S Paudel, Dana C Hammell, Remigius U Agu, Satyanarayana Valiveti, Audra L Stinchcom. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug development and industrial pharmacy. vol 36. issue 9. 2011-02-09. PMID:20545522. |
the nonpsychoactive cannabinoid, cannabidiol (cbd), has great potential for the treatment of chronic and 'breakthrough' pain that may occur in certain conditions like cancer. |
2011-02-09 |
2023-08-12 |
Not clear |
| Justin Thomas Fischedick, Arno Hazekamp, Tjalling Erkelens, Young Hae Choi, Rob Verpoort. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry. vol 71. issue 17-18. 2011-02-04. PMID:21040939. |
metabolic fingerprinting of cannabis sativa l., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. |
2011-02-04 |
2023-08-12 |
Not clear |
| Justin Thomas Fischedick, Arno Hazekamp, Tjalling Erkelens, Young Hae Choi, Rob Verpoort. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry. vol 71. issue 17-18. 2011-02-04. PMID:21040939. |
chemical analysis of cannabis plant material used a gas chromatography flame ionization detection method that was validated for quantitative analysis of cannabis monoterpenoids, sesquiterpenoids, and cannabinoids. |
2011-02-04 |
2023-08-12 |
Not clear |
| Robert Ramer, Anja Rohde, Jutta Merkord, Helga Rohde, Burkhard Hin. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharmaceutical research. vol 27. issue 10. 2011-02-02. PMID:20668920. |
using human lung cancer cells, we evaluated the involvement of plasminogen activator inhibitor-1 (pai-1) in the anti-invasive action of cannabidiol, a non-psychoactive cannabinoid. |
2011-02-02 |
2023-08-12 |
human |
| Erin L Karschner, W David Darwin, Robert S Goodwin, Stephen Wright, Marilyn A Huesti. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical chemistry. vol 57. issue 1. 2011-01-20. PMID:21078841. |
plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. |
2011-01-20 |
2023-08-12 |
Not clear |
| Haleli Sharir, Mary E Aboo. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacology & therapeutics. vol 126. issue 3. 2011-01-13. PMID:20298715. |
whether gpr55 responds to the endocannabinoid ligands anandamide and 2-arachidonylglycerol and the phytocannabinoids, delta-9-tetrahydrocannabidiol and cannabidiol, is cell type and tissue-dependent. |
2011-01-13 |
2023-08-12 |
mouse |
| Joshua A Lile, Thomas H Kelly, Lon R Hay. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol. Clinical neuropharmacology. vol 33. issue 5. 2011-01-06. PMID:20838217. |
the central effects of Δ-tetrahydrocannabinol (Δ-thc), the primary active constituent of cannabis, are attributed to cannabinoid cb1 receptor activity, although clinical evidence is limited. |
2011-01-06 |
2023-08-12 |
human |
| István Katon. Endocannabinoid receptors: CNS localization of the CB₁ cannabinoid receptor. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104380. |
this chapter aims to explain the characteristically wide pharmacological and behavioral profile of the cannabis plant by pointing to the ubiquitous anatomical distribution of cb₁ cannabinoid receptors, its predominant molecular target, throughout the nervous system. |
2011-01-04 |
2023-08-12 |
Not clear |
| F Markus Lewek. Schizophrenia. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104393. |
a possible neurobiological mechanism for the deleterious influence of cannabis use in schizophrenia is discussed, involving the disruption of endogenous cannabinoid signalling and function. |
2011-01-04 |
2023-08-12 |
Not clear |
| Zuzana Justinova, Leigh V Panlilio, Steven R Goldber. Drug addiction. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104390. |
the cannabinoid cb(1) antagonist/inverse agonist rimonabant has been shown to reduce the behavioral effects of stimuli associated with drugs of abuse, including nicotine, alcohol, cocaine, and marijuana. |
2011-01-04 |
2023-08-12 |
Not clear |
| Kirsten R Müller-Vah. Tourette's syndrome. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104394. |
to date, it is unknown whether other drugs that interact with the endocannabinoid receptor system might be more effective in the treatment of ts than smoked marijuana or pure thc. |
2011-01-04 |
2023-08-12 |
Not clear |